Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

A Sequential Cohort Study of Pathogen Reduced Platelet Component Transfusion without Use of Leukocyte Reduction for Hematopoietic Stem Cell Transplant (HSCT): Impact on Clinical Refractoriness

Laurence Corash, MD, Joycelyn Sim, MDMBBS, Wai-Chiu Tsoi, MD, Cheuk Kwong Lee, MD, Rock Y.Y. Leung, MD, Yingjie Liu, MD, Norman Huang, PhD, Clarence C.K. Lam, Hans Vermeij, Adonis Stassinopoulos, PhD BSc, MPhil, MA, Richard J. Benjamin, MD, Albert Kwok Wai Lie, MBBS,FRCP,FRCPath,FRCPA

Blood (2018) 132 (Supplement 1): 1257.

https://doi.org/10.1182/blood-2018-99-112305

Published: 2018

Journal Articles

Potential Mitigation of the Covert Risk of Bacterial Contamination of RBC: Inactivation of Propionibacterium Acnes in RBC Using Amustaline and Glutathione

T Lu, K Goldbeck, M McCormack, Peter Wolfgang Bringmann, PhD, Adonis Stassinopoulos, PhD BSc, MPhil, MA

Blood (2017) 130 (Supplement 1): 2412.

https://doi.org/10.1182/blood.V130.Suppl_1.2412.2412

Published: 2017

Journal Articles

Pathogen Inactivated Platelet Components Used without Leukofiltration, or Gamma Irradiation Show Comparable Therapeutic Efficacy and Safety to Gamma Irradiated and Non-Leukofiltered Conventional Products for the Support of HSCT Patients in Hong Kong

Joycelyn Sim Pui Yin, Rock Leung Yuk Yan, Clarence Lam Chun Kit, Chiu Tsoi Wai, Kwong Lee Cheuk, Albert Lie Kwok Wai, Norman Huang, Salvador Rico, Jin-Sying Lin, Laurence Corash, Adonis Stassinopoulos

Blood (2016) 128 (22): 1454.

https://doi.org/10.1182/blood.V128.22.1454.1454

Published: 2016

Journal Articles

Reinvestigation of the T-Cell Inactivation Achieved for the Prevention of TA GV HD By 2500 Gy of Gamma Irradiation, a Comparison with Pathogen Reduction

Patricia A Merkel, Hannah E Giclas, Andrew Gibula, Gillian Andersen, Vijaya Knight, Jin-Sying Lin, Grace Castro, Jennifer Green, Adonis Stassinopoulos

Blood (2016) 128 (22): 1455.

https://doi.org/10.1182/blood.V128.22.1455.1455

Published: 2016

Journal Articles

Effects of Pooling Multiple Red Blood Cell Units to Improve Storage

Aabhas Mathur, Adonis Stassinopoulos, PhD, John R. Hess, MD, MPH, Mohandas Narla, DSc, Beth H Shaz, MD

Blood (2012) 120 (21): 3437.

https://doi.org/10.1182/blood.V120.21.3437.3437

Published: 2012

Journal Articles

Donor Availability for Extended Phenotype Matching for Transfusion in Thalassemia and Sickle Cell Disease.

Connie M Westhoff, PhD, Marek Simm, MT, Carl Myers, Stella T Chou, MD, Adonis Stassinopoulos, PhD, Beth H Shaz, MD

Blood (2012) 120 (21): 2287.

https://doi.org/10.1182/blood.V120.21.2287.2287

Published: 2012

Journal Articles

Random Healthy Donor Sera Show Varying Effectiveness in Hemolyzing ABO Incompatible Red Blood Cells.

Larry J. Dumont, MBA, PhD, James P. AuBuchon, MD, Louise Herschel, BS, Jill Roger, BS, Thayer White, PhD, Adonis Stassinopoulos, PhD

Blood (2006) 108 (11): 958.

https://doi.org/10.1182/blood.V108.11.958.958

Published: 2006

Journal Articles

Antibodies to S-303 Treated RBC Prepared with the Original Treatment Process (OSRBC) for Pathogen Inactivation Do Not React with RBC Prepared with a Modified S-303 Treatment Process (MSRBC).

Maureen G. Conlan, MD, George Garratty, PhD, FRCPath, Grace Castro, Anna Erickson, Mary Ann Schott, Pat Arndt, David Cook, PhD, Laurence Corash, MD, Adonis Stassinopoulos, PhD

Blood (2005) 106 (11): 430.

https://doi.org/10.1182/blood.V106.11.430.430

Published: 2005

Journal Articles

Antibody Formation to S-303-Treated RBCS in the Setting of Chronic RBC Transfusion.

Maureen G. Conlan, MD, Adonis Stassinopoulos, PhD, George Garratty, PhD, David Wages, MD, PhD, Laurence Corash, MD, Lindsey Wood, PhD, Steven R. Sloan, MD, Richard J. Labotka, MD

Blood (2004) 104 (11): 382.

https://doi.org/10.1182/blood.V104.11.382.382

Published: 2004

Journal Articles

Elimination of Immunoreactivity of Red Cells Treated with a Modified S-303 Pathogen Inactivation Process.

Adonis Stassinopoulos, PhD, Mary Ann Schott, BA, Grace M. Castro, BSc, Lisa M. Turin, BSc

Blood (2004) 104 (11): 2703.

https://doi.org/10.1182/blood.V104.11.2703.2703

Published: 2004

NARROW

A Sequential Cohort Study of Pathogen Reduced Platelet Component Transfusion without Use of Leukocyte Reduction for Hematopoietic Stem Cell Transplant (HSCT): Impact on Clinical Refractoriness

Potential Mitigation of the Covert Risk of Bacterial Contamination of RBC: Inactivation of Propionibacterium Acnes in RBC Using Amustaline and Glutathione

Pathogen Inactivated Platelet Components Used without Leukofiltration, or Gamma Irradiation Show Comparable Therapeutic Efficacy and Safety to Gamma Irradiated and Non-Leukofiltered Conventional Products for the Support of HSCT Patients in Hong Kong

Reinvestigation of the T-Cell Inactivation Achieved for the Prevention of TA GV HD By 2500 Gy of Gamma Irradiation, a Comparison with Pathogen Reduction

Effects of Pooling Multiple Red Blood Cell Units to Improve Storage

Donor Availability for Extended Phenotype Matching for Transfusion in Thalassemia and Sickle Cell Disease.

Random Healthy Donor Sera Show Varying Effectiveness in Hemolyzing ABO Incompatible Red Blood Cells.

Antibodies to S-303 Treated RBC Prepared with the Original Treatment Process (OSRBC) for Pathogen Inactivation Do Not React with RBC Prepared with a Modified S-303 Treatment Process (MSRBC).

Antibody Formation to S-303-Treated RBCS in the Setting of Chronic RBC Transfusion.

Elimination of Immunoreactivity of Red Cells Treated with a Modified S-303 Pathogen Inactivation Process.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only